semaglutide nejm weight loss Tirzepatide vs for Obesity – NEJM, May 2025 Relevant to endocrinology, internal medicine, cardiology, obesity medicine • Tirzepatide: −20.2% at 72 wks • Semaglutide: −13.7% • Greater waist reduction In the SURMOUNT-5 phase 3b

"Health isn't about shrinking yourself at all costs

The RESTORE trial remains actively recruiting and tracking participants to enrich the data pool and further elucidate dose-response relationships and safety profiles

10.1001/jama.2021.23619 35

Together, they offer a holistic approach to weight management and overall health

Dramatic changes are unlikely initially

CrossRef Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitus Seyed Saman Talebi, Shabnam Rezaie, Minoo Sadat Hajmiri, Maryam Zamanirafe, Akram Ranjbar, Heresh Moridi, Mahtabalsadat Mirjalili, Maryam Mehrpooya Naunyn-Schmiedeberg's Archives of Pharmacology.2024